论文部分内容阅读
目的观察厄贝沙坦治疗原发性高血压的应用效果。方法选取医院收治的原发性高血压患者180例为研究对象,随机分为观察组和对照组,每组90例。观察组给予厄贝沙坦治疗,对照组给予依那普利治疗,比较2组患者血压、心率,实验室指标及不良反应发生率。结果治疗前,2组患者血压、心率比较差异无统计学意义(P>0.05)。治疗后,2组患者血压均较治疗前降低(P<0.01);2组患者经相关治疗后,尿素氮、胆固醇、肌酐、三酰甘油、谷丙转氨酶水平比较,差异无统计学意义(P>0.05);观察组不良反应发生率为4.44%,低于对照组的18.89%(P<0.01)。结论原发性高血压患者接受厄贝沙坦治疗,可以较好控制血压水平,且不会对患者的心功能造成影响,不良反应少,值得临床推广应用。
Objective To observe the effect of irbesartan in treating essential hypertension. Methods A total of 180 patients with primary hypertension admitted to our hospital were selected as study subjects and randomly divided into observation group and control group with 90 cases in each group. The observation group was treated with irbesartan, and the control group with enalapril. The blood pressure, heart rate, laboratory parameters and the incidence of adverse reactions were compared between the two groups. Results Before treatment, there was no significant difference in blood pressure and heart rate between the two groups (P> 0.05). After treatment, the blood pressure in both groups was lower than that before treatment (P <0.01). There was no significant difference in blood urea nitrogen, cholesterol, creatinine, triglyceride, and alanine aminotransferase levels after treatment > 0.05). The incidence of adverse reactions in the observation group was 4.44%, which was lower than that in the control group (18.89%, P <0.01). Conclusion Irbesartan treatment in patients with essential hypertension can better control blood pressure levels, and will not affect the patient’s cardiac function, fewer adverse reactions, it is worth promoting the clinical application.